FDA stops firm marketing unapproved cold medicines

0 comments

Posted on 10th April 2009 by Gordon Johnson in Uncategorized

, , , , , , , ,

Date: 4/10/2009

WASHINGTON (AP) — Federal regulators have secured a court order barring a New Jersey pharmaceutical company from distributing more than 50 unapproved cough and cold medicines.

The Food and Drug Administration said Friday that East Windsor, N.J.-based Advent Pharmaceuticals continued to market the medications despite prior warnings from regulators. The company also failed to correct numerous manufacturing problems identified by FDA inspectors.

Drug manufacturers in the U.S. are required to submit their products to the FDA for premarket approval to guarantee they are safe and effective. The unapproved products marketed by Advent and its subsidiary Neilgen Pharmaceuticals include: BP Allergy Junior Suspension, RE All 12 Suspension and many others.

Neilgen, which also does business as Unigen Pharmaceuticals, is based in Westminster, Md.

“Consumers in possession of these products should discontinue using them and discuss FDA-approved treatments with their health care professional,” the FDA said in a statement.

Company executives Bharat Patel and Pragna Patel agreed to destroy their inventory of unapproved drugs, under a consent degree handed down in the U.S. District Court of Maryland. The agreement also bars the executives from manufacturing any new drugs without FDA approval and requires them to hire outside consultants to assess their operations before resuming production.

Company leaders did not immediately respond to calls for comment Friday afternoon.

Friday’s action comes the same week the FDA ordered a number of medical device manufacturers to submit data on products that were never approved. The devices, which range from pacemaker generators to dental implants, were released to market before the 1976 law which gave FDA authority to regulate new devices.

Copyright 2009 The Associated Press.

Limit on cold remedies for kids was FDA's idea

0 comments

Posted on 11th October 2008 by Gordon Johnson in Uncategorized

, , , , , , , ,

Date: 10/10/2008 5:59 PM

By RICARDO ALONSO-ZALDIVAR
Associated Press Writer

WASHINGTON (AP) _ When drug makers made a surprise announcement this week that they no longer recommend cough and cold remedies for youngsters under 4, they didn’t let on that it was the government’s idea.

And why age 4 rather than the age 6 that pediatricians’ wanted?

Because the Food and Drug Administration suggested that, too.

FDA officials proposed the cutoff earlier this year in private discussions with the industry, government and industry officials confirmed Friday. The companies agreed, and this week announced they were “voluntarily” changing their advice to parents.

The maneuvering is an example of how government health officials and the industries they regulate seek to come to an accommodation behind the scenes on tricky issues. In this case, there is scant evidence that the widely used over-the-counter medicines really do work in children. Emergency-room data shows that they sicken some 7,000 kids a year, mostly because of overdoses.

“There is a delicate dance between how much legal authority the FDA has and their use of the bully pulpit for getting some sort of compromise,” said Dr. Joshua Sharfstein, Baltimore’s health commissioner.

Sharfstein and other pediatricians have asked the FDA to ban the cold products for children under 6. A panel of independent advisers to the FDA strongly seconded that recommendation. But the agency took a different approach.

“The analysis that led to the under-4 cutoff was performed by FDA,” said Rita Chappelle, a spokeswoman for the agency. “We suggested it, and then it was voluntarily adopted by industry. (They) did not come up with the proposal themselves.”

Even now, however, the reasons for setting a cutoff specifically for kids under 4 remain unclear.

The FDA says it settled on age 4 after a careful data review and a vigorous internal debate. Officials said emergency room data shows that most of the problems with the drugs involve kids under 4. But the FDA refused to release the hospital data, which comes from a study by the Centers for Disease Control and Prevention. And CDC said Friday it could not immediately supply a detailed breakdown.

Still, some of the FDA’s independent advisers question the under-4 recommendation.

“There was no data suggesting that the drugs were effective in kids under 12,” said Sean Hennessy, a professor of epidemiology and biostatistics at the University of Pennsylvania. “I don’t see how that’s a fully rational approach to the problem.”

The Consumer Healthcare Products Association, which represents the industry, acknowledged the new safety recommendation was the FDA’s idea.

“CHPA moved forward with voluntary label changes at the suggestion of FDA because all the available data shows a clear distinction in the rates of adverse events in children under age four,” said Elizabeth Funderburk, a spokeswoman for the trade group. “Industry has always and will continue to make decisions based on the science as well as what is in the best interest of parents and their families.”

The industry has taken other precautions as well. Drug makers are advising parents not to give their children antihistamines to make them sleepy. The companies are also adopting better child-resistant packaging, and they are expanding an educational campaign aimed at parents.

Meanwhile, the FDA says it intends to revise government regulations for OTC cough and cold medicines and may eventually require much more sweeping changes that reach kids all the way up to the teenage years.

___

On the Net:

FDA statement on cold remedies:

http://tinyurl.com/52u69h

Copyright 2008 The Associated Press.

FDA: No quick decision on cold medicines for kids

0 comments

Posted on 2nd October 2008 by Gordon Johnson in Uncategorized

, , , , , , ,

Date: 10/2/2008 2:00 PM

By RICARDO ALONSO-ZALDIVAR
Associated Press Writer

WASHINGTON (AP) _ A top government health official rejected the idea of an immediate ban on cough and cold medicines for young children, saying it might cause unintended harm.

Food and Drug Administration officials at a public hearing Thursday said they need to gather more data on whether over-the-counter remedies are safe and effective for children ages 2-6.

The FDA is also worried that a ban — as sought by leading pediatricians’ groups — might only drive parents to give adult medicines to their youngsters.

“That is a concern for us,” said Dr. John Jenkins, who heads the FDA’s Office of New Drugs. “We do not want to do something that we think will have a positive impact, only to have an unintended negative. That could be an even worse situation.”

With a new cold season coming, pediatricians are urging the government to demand a recall of over-the-counter cough and cold medicines for children younger than 6. The effectiveness of the medicines in children was never scientifically established, critics say, and problems with the drugs send thousands of kids to the emergency room every year.

“When a treatment is ineffective, its risks — unless zero — always exceed its benefits,” Dr. Michael Shannon of Children’s Hospital in Boston told the FDA panel.

The FDA this year warned against giving OTC cold medicines to children younger than 2. At that time, officials said they expected to decide by spring on recommendations for youngsters up to 11. Now the agency is seeking more advice from doctors, industry and consumers — and officials are not giving a timetable for a decision.

U.S. families spend at least $286 million a year on such cough and cold remedies for children, according to the Nielsen Co. market research firm. In any given week the medicines are used by an estimated 10 percent of all children, with the biggest exposure among 2- to 5-year-olds, a recent Boston University report found.

But colds usually clear up on their own after a few days. Many doctors say rest and plenty of fluids are what it takes to get over a cold.

The industry says OTC medicines have been used for decades in treating kids’ colds and are safe for those older than 2. Nonetheless, manufacturers are planning to carry out new studies involving the most common ingredients in the medications. The companies voluntarily stopped selling cough and cold medicines for babies and toddlers last fall.

FDA advisers said that was not enough and recommended that the drugs not be used for children younger than 6. An expert panel said children older than 2 could keep taking the medications while studies are undertaken to settle scientific questions about safety and effectiveness.

It turns out that when the FDA set standards for cough and cold medicines some 30 years ago, no separate studies were done for kids.

Cough and cold medicines send about 7,000 children to hospital emergency rooms each year with symptoms ranging from hives and drowsiness to unsteady walking. Low doses of a medicine are not likely to cause a problem; the main risk comes from unintentional overdoses.

The same ingredients usually are found in different products. For example, giving a child a cough syrup and a decongestant could inadvertently lead to an overdose.

The Consumer Healthcare Products Association, which represents the manufacturers, says preventable errors are the problem, not the safety of the ingredients in the medicines. The industry is starting an educational campaign aimed at parents, doctors and day care providers on the importance of following directions and storing medicines in places where kids cannot get at them.

“The data clearly show a majority of adverse events are direct result of misuse of our products,” said Linda Suydam, who heads the industry group.

Baltimore health commissioner Dr. Joshua Sharfstein sought to reassure FDA officials worried about unintended consequences if the government moves to restrict the medications and parents start dispensing adult drugs to their preschoolers. Sharfstein said the state of Maryland saw an immediate benefit after OTC cough and cold remedies for tots were removed from store shelves last fall. Calls to poison control about problems with the medicines involving children younger than 2 dropped by 40 percent, from 99 to 60, in the first six months of this year when compared with 2007. Calls involving children 2 to 6 also dropped, but by much less.

“The feared increases in poisonings simply did not happen,” said Sharfstein. “In fact, the opposite occurred.”

Copyright 2008 The Associated Press.

FDA urged to recall cold medicines for youngsters

0 comments

Posted on 2nd October 2008 by Gordon Johnson in Uncategorized

, , , , , , ,

Date: 10/2/2008 3:14 AM

By RICARDO ALONSO-ZALDIVAR
Associated Press Writer

WASHINGTON (AP) _ With a new cold season coming, the government is trying once more to decide what to do about over-the-counter medicines for kids’ coughs and sniffles. Doctors question the drugs’ benefits and worry about their risks.

Pediatricians are urging the Food and Drug Administration, which scheduled a public hearing Thursday on the issue, to demand a recall of the medicines for children younger than 6.

“Parents should know that there is less evidence than ever to support the use of over-the-counter cough and cold medicines for young children,” said Dr. Joshua Sharfstein, Baltimore’s health commissioner. “There is nothing that is holding the FDA back from asking for a voluntary recall now of products marketed to kids under 6.”

U.S. families spend at least $286 million a year on such cough and cold remedies for children, according to the Nielsen Co. market research firm. In any given week the medicines are used by an estimated 10 percent of all children, with the biggest exposure among 2- to 5-year-olds, a recent Boston University report found.

But colds usually clear up on their own after a few days. Many doctors say rest and plenty of fluids are what it takes to get over a cold.

The FDA this year warned against giving OTC cold medicines to children younger than 2. At that time, officials said they expected to decide by spring on recommendations for youngsters up to 11. Now the agency is seeking more advice from doctors, industry and consumers.

The industry says OTC medicines have been used for decades in treating kids’ colds and are safe for those older than 2. Nonetheless, manufacturers are carrying out new studies involving the most common ingredients in the medications. The companies voluntarily stopped selling cough and cold medicines for babies and toddlers last fall.

FDA advisers said that was not enough and recommended that the drugs not be used for children younger than 6. An expert panel said older children could keep taking the medications while studies are undertaken to settle scientific questions about safety and effectiveness.

It turns out that when the FDA set standards for cough and cold medicines some 30 years ago, no separate studies were done for kids.

Cough and cold medicines send about 7,000 children to hospital emergency rooms each year with symptoms ranging from hives and drowsiness to unsteady walking. Low doses of a medicine are not likely to cause a problem; the main risk comes from unintentional overdoses.

The same ingredients usually are found in different products. For example, giving a child a cough syrup and a decongestant could inadvertently lead to an overdose.

The Consumer Healthcare Products Association, which represents the manufacturers, says preventable errors are the problem, not the safety of the ingredients in the medicines. The industry is starting an educational campaign aimed at parents, doctors and day care providers on the importance of following directions and storing medicines in places where kids cannot get at them.

But Sharfstein said Maryland saw an immediate benefit after OTC cough and cold remedies for tots were removed from store shelves last fall. Calls to poison control about problems with the medicines involving children younger than 2 dropped by 40 percent, from 99 to 60, in the first six months of this year when compared with 2007. Calls involving children 2 to 6 also dropped, but by much less.

___

On the Net:

Food and Drug Administration background: http://tinyurl.com/3emy54

Copyright 2008 The Associated Press.